Perlara PBC careers

Perlstein Lab PBC (PLab) is the first orphan therapeutics Public Benefit Corporation accelerating drug discovery for the 5,000+ rare genetic diseases.

PLab uses a platform of CRISPR-engineered animals (yeast, nematodes, fruit flies and zebrafish) in phenotypic screens to identify orphan drug candidates that reverse disease much faster and cheaper than current approaches.

Our proof-of-concept diseases are Niemann-Pick Type C, a lysosomal storage disorder first described nearly a century ago, and NGLY1 Deficiency, a congenital disorder of glycosylation first diagnosed last year. In addition to these, we are incorporating two additional diseases in our pipeline, namely Batten’s disease and Leigh Syndrome.